Auxilium On a Roll ...
Health Care: Drugs
Allergan Inc. (AGN: NYSE)
$88.58 0.49 | 0.56%
06/04/12 - 04:02 PM ET
Ratio Comparisons
| Company | Industry | S&P 500 | |
| Valuation Ratios | |||
|---|---|---|---|
| P/E Ratio (TTM) | 27.20 | 28.50 | 17.70 |
| P/E High - Last 5 Yrs | n.a. | 189.00 | 67.70 |
| P/E Low - Last 5 Yrs | n.a. | 18.60 | 12.50 |
| Beta | 0.81 | 0.62 | 0.98 |
| Price to Sales (TTM) | 4.83 | 4.29 | 1.42 |
| Price to Book (MRQ) | 4.90 | 4.39 | 2.41 |
| Price to Tangible Book (MRQ) | 12.06 | 14.20 | 5.08 |
| Price to Cash Flow (TTM) | 21.20 | 19.50 | 9.80 |
| Price to Free Cash Flow (TTM) | 31.40 | -327.00 | 17.40 |
| Dividends | |||
| Dividend Yield (%) | 0.20 | 0.90 | 2.10 |
| Dividend Yield - 5 Yr Avg (%) | 0.30 | 0.80 | 2.20 |
| Dividend 5 Yr Growth Rate (%) | n.a. | 42.32 | -0.76 |
| Payout Ratio (TTM) | 6.00 | 51.00 | 30.00 |
| Sales (MRQ) vs Qtr 1 Yr Ago (%) | 9.50 | 15.60 | 11.80 |
| Sales (TTM) vs TTM 1 Yr Ago (%) | 10.20 | 9.00 | 9.20 |
| Growth Rates (%) | |||
| Sales - 5 Yr Growth Rate (%) | 9.06 | 6.32 | 1.79 |
| EPS (MRQ) vs Qtr 1 Yr Ago (%) | 45.20 | -2.50 | 17.50 |
| EPS (TTM) vs TTM 1 Yr Ago (%) | 45.20 | -2.50 | 17.50 |
| EPS - 5 Yr Growth Rate (%) | n.a. | 24.63 | -1.66 |
| Capital Spending - 5 Yr Growth Rate (%) | -33.82 | -6.43 | -1.17 |
| Financial Strength | |||
| Quick Ratio (MRQ) | 3.60 | 1.30 | 1.10 |
| Current Ratio (MRQ) | 4.40 | 1.80 | 1.60 |
| LT Debt to Equity (MRQ) | 0.28 | 0.29 | 0.82 |
| Total Debt to Equity (MRQ) | 0.29 | 0.37 | 0.96 |
| Interest Coverage (TTM) | 23.30 | 9.20 | 5.50 |
| Profitability Ratios (%) | |||
| Gross Margin (TTM) | 88.60 | 75.60 | 46.90 |
| Gross Margin - 5 Yr Avg | 87.00 | 75.30 | 47.70 |
| EBITD Margin (TTM) | 31.30 | 29.40 | 18.90 |
| EBITD - 5 Yr Avg | 22.95 | 0.00 | 0.00 |
| Pre-Tax Margin (TTM) | 25.40 | 18.00 | 12.10 |
| Pre-Tax Margin - 5 Yr Avg | 16.40 | 11.80 | 10.30 |
| Management Effectiveness (%) | |||
| Net Profit Margin (TTM) | 0.18 | 0.14 | 0.09 |
| Net Profit Margin - 5 Yr Avg | 11.40 | 8.60 | 7.00 |
| Return on Assets (TTM) | 11.60 | 7.30 | 3.10 |
| Return on Assets - 5 Yr Avg | 7.00 | 4.60 | 2.50 |
| Return on Investment (TTM) | 14.40 | 10.40 | 7.90 |
| Return on Investment - 5 Yr Avg | 8.70 | 6.50 | 6.50 |
| Efficiency | |||
| Revenue/Employee (TTM) | 553,980.00 | 404,888.00 | 449,376.00 |
| Net Income/Employee (TTM) | 100,600.00 | 57,122.00 | 39,003.00 |
| Receivable Turnover (TTM) | 7.30 | 4.70 | 7.60 |
| Inventory Turnover (TTM) | 2.50 | 1.70 | 8.30 |
| Asset Turnover (TTM) | 0.60 | 0.60 | 0.40 |
Portfolios with AGN
- Portfolio NameUser Type
- UserOil/Gas Feb 2012
- Contributor7 Stocks Set To Rise at Lea...
- UserCLUBCAR47 Portfolio 1
- UserLes's Picks
- ProBridger Management
- ContributorTop 20 Stocks With Large Se...
- ContributorRocket Stocks for the Week ...
- Contributor10 Pharmaceutical Stocks Wi...
- ContributorCramer's Openings in Health...
- ContributorCramer's Vice and Vanity St...
Latest AGN Headlines from TheStreet
- Allergan Stock To Go Ex-dividend Tomorrow (AGN) 05.21.12 | 09:05 am
- Ex-Dividend Stocks: Thomson Reuters, Infosys 05.21.12 | 05:05 am
- Cramer's 'Mad Money' Recap: 7 Stocks to Scoop Up When On Sale 05.09.12 | 08:05 pm
- Allergan Inc. (AGN): Today's Featured Drugs Winner 05.03.12 | 05:05 pm
- Allergan Management Discusses Q1 2012 Results - Earnings Call Transcript 05.02.12 | 04:05 pm
- 3 Stocks I Saw on TV, May 2
05.02.12 | 08:05 am - The Week Ahead: Jobs Data; Earnings from MasterCard, Visa, Whole Foods 04.29.12 | 06:04 pm
- Allergan Stock Hits New 52-Week High (AGN) 04.26.12 | 01:04 pm
- 3 Stocks I Saw on TV, April 13 04.13.12 | 08:04 am
- Cramer's 'Mad Money' Recap: Love and Hip Stocks (Final) 04.12.12 | 06:04 pm
Press Releases for AGN
- Allergan Reports First Quarter 2012 Operating Results - Business Wire 05.02.12 | 09:05 am
- BOTOX® Cosmetic (onabotulinumtoxinA) Celebrates 10-Year Anniversary Of U.S. Food And Drug Administration Approval - Business Wire 04.13.12 | 09:04 am
- Allergan Announces Quarterly Conference Call - Business Wire 04.06.12 | 01:04 pm
- Allergan Announces Positive Top-Line Results From Phase III BOTOX® Overactive Bladder Program - Business Wire 03.28.12 | 09:03 am
- U.S. Federal Court Finds In Favor Of Allergan, Inc. And Issues Permanent Injunction Against Merz Pharmaceuticals And Merz Aesthetics - Business Wire 03.12.12 | 09:03 am
- Allergan Announces Research & Development Technology Review - Business Wire 02.15.12 | 04:02 pm
- Allergan Reports Fourth Quarter 2011 Operating Results - Business Wire 02.02.12 | 09:02 am
- Allergan Announces Quarterly Conference Call - Business Wire 01.06.12 | 06:01 pm
- Actress Christina Hendricks Urges Women To Join Her In The Final Weeks Of The LATISSE® Wishes Challenge To Increase Money Raised For The Make-A-Wish Foundation® From $390,000 To Campaign Goal Of $500,000 - PR Newswire 11.09.11 | 08:11 am
- Allergan Reports Third Quarter 2011 Operating Results - Business Wire 10.26.11 | 09:10 am
Partner Headlines for AGN
- Time To Take Another Look At The Biotechnology Sector - Seeking Alpha 04.09.12 | 09:04 am
- Cracker Barrel and Other Stocks Insiders Are Buying - Benzinga 04.06.12 | 06:04 am
- Court Deals Blow to Botox Competitor - Analyst Blog - Zacks 03.16.12 | 05:03 pm
- MAP Pharma: Making Money From Migraines - Seeking Alpha 03.11.12 | 09:03 am
- Cramer's Mad Money - 15 Things To Watch This Week (1/27/12) - Seeking Alpha 01.29.12 | 07:01 am
- 6 Drug Companies Favored By Hedge Funds - Seeking Alpha 01.05.12 | 09:01 am
- ETF Showdown: Fun With Pharma - Benzinga 12.30.11 | 04:12 pm
- A Look At Atalanta Sosnoff Capital's Top Buys - Seeking Alpha 11.17.11 | 08:11 am
- Medicis Misses Zacks Consensus - Analyst Blog - Zacks 11.11.11 | 10:11 am
- A Look at The New DRGS ETN - Benzinga 10.31.11 | 01:10 pm
